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Abstract
Background: Mechanically ventilated patients with COVID-19 have a mortality of 24–53%, in part due to distal
mucopurulent secretions interfering with ventilation. DNA from neutrophil extracellular traps (NETs) contribute to
the viscosity of mucopurulent secretions and NETs are found in the serum of COVID-19 patients. Dornase alfa is
recombinant human DNase 1 and is used to digest DNA in mucoid sputum. Here, we report a single-center case
series where dornase alfa was co-administered with albuterol through an in-line nebulizer system.
Methods: Demographic and clinical data were collected from the electronic medical records of five mechanically
ventilated patients with COVID-19—including three requiring veno-venous extracorporeal membrane
oxygenation—treated with nebulized in-line endotracheal dornase alfa and albuterol, between March 31 and April
24, 2020. Data on tolerability and response were analyzed.
Results: The fraction of inspired oxygen requirements was reduced for all five patients after initiating dornase alfa
administration. All patients were successfully extubated, discharged from hospital and remain alive. No drugassociated toxicities were identified.
Conclusions: Results suggest that dornase alfa will be well-tolerated by patients with severe COVID-19. Clinical trials
are required to formally test the dosing, safety, and efficacy of dornase alfa in COVID-19, and several have been
recently registered.
Keywords: SARS-CoV-2, COVID-19, Coronavirus, Mucopurulent secretions, Dornase alfa, Neutrophil extracellular
traps, ARDS, VV-ECMO

Background
Critically ill patients with coronavirus disease 2019
(COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), progress to hypoxemic and then mixed respiratory failure, secondary to
acute respiratory distress syndrome (ARDS) (Marini and
Gattinoni 2020; Greenland et al. 2020). Approximately
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79–88% of patients admitted to the intensive care unit
(ICU) with COVID-19 require intubation and mechanical ventilation, with a mortality of 24–53% (Cummings
et al. 2020; Grasselli et al. 2020; Richardson et al. 2020;
Docherty et al. 2020). ARDS in COVID-19 is characterized by respiratory failure, in part attributable to distally
located mucopurulent secretions.
Dornase alfa (Pulmozyme®) is recombinant human
DNase 1 and a safe mucolytic that is administered in
nebulized form. It is FDA-approved in combination with
standard therapies for patients with cystic fibrosis to improve sputum clearance and pulmonary function (Yang
and Montgomery 2018). It is also used off-label as a mucolytic in other diseases, including ARDS (Morris and
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Mullan 2004; ClinicalTrials.gov [Internet] 2019). A
mechanism by which dornase alfa might improve ventilation is by reducing the DNA-mediated viscosity of
neutrophil-rich secretions (Papayannopoulos et al. 2011).
There are multiple sources for the DNA in mucoid sputum, one of which is neutrophil extracellular traps
(NETs). Recently, we collaboratively reported that in the
discarded serum of patients with COVID-19, the levels
of NETs were increased and correlated with lactate dehydrogenase (LDH), D-dimer, and C-reactive protein
(CRP) levels (Zuo et al. 2020). Subsequently, NETcontaining microthrombi and increased neutrophilplatelet infiltration in pulmonary autopsies from
COVID-19 patients was reported (Becker 2020; Fox
et al. 2020; Middleton et al. 2020; Schonrich et al. 2020;
Tay et al. 2020; Varga et al. 2020; Leppkes et al. 2020).
Notably, targeting NETs reduces mortality in animal
models of acute lung injury (Barnes et al. 2020; Adrover
et al. 2020; Caudrillier et al. 2012; Lefrancais et al. 2018;
Thomas et al. 2012). Despite recognition that mucolytic
treatment may be beneficial for patients with COVID-19
(12, (Earhart et al. 2020), administration of nebulized
medications, such as dornase alfa, have been limited due
to risk of viral aerosolization. If risk of viral aerosolization can be avoided, dornase alfa may benefit patients
with severe COVID-19 by acting as a mucolytic and by
reducing NET levels in the lungs, thereby improving
oxygenation and ventilation. We report the clinical
course, safety, and outcomes after nebulized in-line
endotracheal dornase alfa treatment for five intubated
and mechanically ventilated patients with PCRconfirmed COVID-19.

Methods
The Northwell Health institutional review board that focuses
on COVID-19 research approved this case series as
minimal-risk research using de-identified data from routine
clinical practice. Data were collected from the enterprise
health record (Sunrise Clinical Manager; Allscripts) reporting
database, and included patient demographics, comorbidities,
inpatient medications, laboratory studies, treatment, and outcomes. We further obtained longitudinal values of the fraction of inspired oxygen (FiO2) and of the arterial partial
pressure of carbon dioxide (PaCO2) as measures of respiratory function during treatment. Lung mechanics were
assessed by obtaining mechanical power of the respiratory
system (MP) and mean airway pressure (Paw). FiO2 values of
the circuit were reported for those patients who required
veno-venous extracorporeal membrane oxygenation (VVECMO). Ferritin, CRP, LDH, and D-dimer were obtained as
measures of systemic disease and inflammation. Not all patients had laboratory investigations on the same days in relation to the nebulized and co-administered dornase alfa and
albuterol (nDA + A) treatment. In the following case
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synopses, each measurement is therefore followed by the day
in relation to the first day of treatment with nDA + A (e.g., d
2 for the second day of treatment with nDA + A or d − 1 for
the day before nDA + A treatment was initiated). Relevant
nDA toxicities (hoarseness, rash, hypersensitivity reactions
and hemoptysis) were clinically monitored. Hoarseness was
assessed post-intubation. Rash was assessed daily via physical
exam. Hypersensitivity reactions were determined via physical exam, vital signs, and vasopressor requirements.
Hemoptysis was assessed in intubated patients by endotracheal tube visual inspection.

Results
Five patients treated with dornase alfa between March
31, 2020 and April 24, 2020 were identified. These patients had met the Berlin criteria for ARDS and were
treated with ventilator strategies guided by the ARDS
Net protocol at North Shore University Hospital within
Northwell Health (Durante et al. 2002). These patients
had been treated with dornase alfa because they required
high levels of FiO2 and had elevated ventilation demands. All patients received the same treatment doses:
nebulized dornase alfa (2.5 mg) co-administered twice
daily with the short-acting β2-agonist albuterol (2.5 mg)
to improve delivery to the alveoli (referred to as nDA +
A). Of note, β2-adrenoreceptor agonism may also inhibit
NET formation by direct action on neutrophils (Marino
et al. 2018). The treatment was administered with an
Aerogen® Solo in-line nebulizer to avoid open aerosol
generation, which would place staff at risk of exposure
to SARS-CoV-2.
The patient characteristics are summarized in Table 1.
Patients were treated with nDA + A between 3 to 25
days. The most common characteristics of the patients
included obesity (BMI ≥ 30) and four of the patients had
hypertension. Four patients received methylprednisolone
dosed at 1-2 mg/kg/day. All patients were treated with
full dose or prophylactic dose anticoagulation for thrombosis. All other medications that were administered during the course of hospitalization were considered
standard of care (STC) at the time of treatment and are
summarized in Table S1. No adverse events related to
nDA + A treatment were observed for any of the patients
throughout the duration of the study. The clinical course
of the five patients treated with nDA + A is summarized
in Fig. 1. Figures 2 and 3 display the longitudinal, ventilatory, and inflammatory markers for each patient.
Patient 1 is a 56-year-old Hispanic woman who presented in respiratory distress. Her respiratory status deteriorated over 48 h, requiring intubation and transfer to
the ICU. She was treated with nDA + A for 6 days, starting from day 10 of intubation. The FiO2 requirement decreased from 70% (d − 1) to 30% (d 6), PaCO2 from 58
(d − 1) to 37 mmHg (d 7), ferritin from 1803 (d − 1) to
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Table 1 Patient data from five patients with COVID-19 who received dornase alfa with albuterol March–April, 2020
Patient

1

2

3

4

5

Date of admission

29 March

4 April

16 March

16 March

26 March

Age

56

34

65

31

34

Gender

F

M

M

M

F

Ethnicity

Hispanic

White

Asian

Hispanic

Black

BMI

38

41

32

30

38

Date of ICU admission

31 March

4 April

16 March

18 March

26 March

Hypertension

Yes

Yes

Yes

Yes

Diabetes mellitus, type 2

Yes

Asthma

Yes

Clinical Characteristics

Comorbidities

Hyperlipidemia

Yes

Yes

Yes

Migraine

Yes

Chronic gastritis

Yes

ECMO
Date of ECMO initiation

–

4 April

–

27 March

28 March

Date of ECMO cessation

–

16 April

–

10 April

20 April

Dornase alfa (DA) + albuterol (A) parameters
Administration (DA: 2.5 mg, A: 2.5 mg, both twice daily using the Aerogen® Solo nebulizer)
Date of DA + A initiation

9 April

4 April

31 March

1 April

31 March

Date of DA + A cessation

14 April

6 April

8 April

19 April

24 April

Toxicities

None

None

None

None

None

Yes

Yes

Yes

Yes

Yes

Yes

Other COVID-19 treatment
Methylprednisolone
Anakinra
CytoSorb
Anticoagulants

Yes
a

Enoxaparin

40 mg BID

Argatroban

120 mg BID

40 mg BID

Yes

Heparin gtt

100 mg BID

120 mg BID

Yes

Yes

Yes

Yes

Venous thromboembolism

None

None

None

Right SDVT
Right CVT

None

Current State

ICU discharge

ICU discharge

ICU discharge

ICU discharge

ICU discharge

a

Patients were not on simultaneous anticoagulation therapies. BMI Body mass index, ICU Intensive care unit, ECMO Extracorporeal membrane oxygenation, BID Bis
in die (twice a day), gtt Guttae (intravenous drip), SDVT Soleal deep vein thrombosis, CVT Cephalic vein thrombosis

472 ng/mL (d 6), and D-dimer from 1619 (d − 1) to 563
ng/mL (d 6). MP had increased from 16.48 (d − 1) to
20.91 J/minute (d 6), and Paw from 12 (d − 1) to 20
cmH2O (d 6). Minimal changes were noted in CRP and
LDH. The patient underwent a tracheostomy after 23
days of endotracheal intubation and was able to be
decannulated 19 days later. She was discharged to a rehabilitation facility after a total hospital stay of 82 days.
Patient 2 is a 34-year-old white man who presented to
the hospital in diabetic ketoacidosis without prior history

of diabetes mellitus. He was intubated on admission and
initiated on VV-ECMO. He received nDA + A for 3 days
and was de-cannulated after 12 days. No change in
ECMO settings occurred during treatment time. The
FiO2 requirement decreased from 100% (d 0) to 80% (d
3), MP from 36.38 (d 0) to 12.03 J/min (d 3), Paw from
36.38 (d 0) to 12.03 cmH2O (d 3), CRP from 14.14 (d 0)
to 2.41 mg/dL (d 3), ferritin from 12,281 (d 0) to 5453
ng/mL (d 3), and D-dimer from 5210 (d 0) to 2099 ng/
mL (d 3). Minimal changes were noted in PaCO2 and
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Fig. 1 Overview of the clinical course of five patients treated with nebulized dornase alfa + albuterol (nDA + A)

LDH. The patient was able to be extubated after 30 days
of endotracheal intubation (VV-ECMO the first 12 days).
He was discharged to a rehabilitation facility after a total
hospital stay of 75 days.
Patient 3 is a 65-year-old Asian man who was admitted directly to the ICU for respiratory distress and intubated 3 days later. Twelve days after intubation, he was
started on 9 days of nDA + A treatment. The FiO2 requirement decreased from 50% (d − 1) to 40% (d 7),
PaCO2 from 55 (d 0) to 43 mmHg (d 6), and CRP from
22.07 (d 0) to 26.48 mg/dL (d 6). Minimal changes were
noted in MP, Paw, ferritin, LDH, and D-dimer. He was
extubated 1 day after the completion of the nDA + A

course. Five days later, he was re-intubated for an additional 4 days due to mental status changes and failure
to protect his airway. The patient was extubated in ICU
care 30 days after his initial endotracheal intubation. He
subsequently developed a right colonic and small bowel
perforation requiring the placement of multiple drains.
He required the initiation of total parenteral nutrition
until he was able to tolerate enteral feeds. Surgery was
never required. He was discharged to a rehabilitation facility after a total hospital stay of 97 days.
Patient 4 is a 31-year-old Hispanic man who was intubated and transferred to the ICU from the Internal
Medicine service 2 days after presenting with respiratory

Fig. 2 Patient-level data of respiratory function during treatment with nebulized dornase alfa + albuterol (nDA + A). Values were extracted from
the medical records the day before and up to the seven days after the initiation of treatment. Values are graphed in black for patients after they
ceased nDA + A treatment. Dashed lines indicate patients on VV-ECMO. Not all markers were measured daily for every patient. FiO2: fraction of
inspired oxygen; PaCO2: partial pressure of carbon dioxide
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Fig. 3 Patient-level data of systemic disease during treatment with nebulized dornase alfa + albuterol (nDA + A). Values were extracted from the
medical records the day before and up to the seven days after the initiation of treatment. Values are graphed in black for patients after they
ceased nDA + A treatment. Dashed lines indicate patients on VV-ECMO. Not all markers were measured daily for every patient. CRP: C-reactive
protein; LDH: lactate dehydrogenase

distress. Nine days after intubation, he was initiated on
VV-ECMO. Five days after cannulation, he was started
on the nDA + A treatment. After ten days, he was decannulated and remained intubated for ten days while
continuing the nDA + A treatment. No change in ECMO

settings occurred during treatment time. He was then
extubated and discharged to the floor. The FiO2 requirement decreased from 90% (d − 1) to 21% (d 7), Paw from
19 (d − 1) to 16 cmH2O (d 7), and LDH from 1054 (d −
1) to 451 U/L (d 7). Ferritin initially decreased from
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1669 (d − 1) to 387 ng/mL (d 7). On day 15 of treatment,
he developed methicillin-resistant Staphylococcus aureus
(MRSA) pneumonia and bacteremia. Ferritin thus increased to 1619 ng/mL (d 13) prior to decreasing to 555
ng/mL (d 19) with antibiotic treatment. Minimal
changes were noted in MP, PaCO2, CRP, and D-dimer.
He was transferred to an acute inpatient rehabilitation
facility after a total hospital stay of 73 days.
Patient 5 is a 34-year-old black woman who was intubated at an outside hospital, then transferred to the
North Shore University Hospital ICU. Two days later,
she was cannulated for VV-ECMO. She required VVECMO for 24 days and was intubated for a total of 30
days. She was treated with nDA + A for 25 days starting
on day 4 following cannulation for VV-ECMO. While
on VV-ECMO for the first 5 days, CytoSorb therapy was
applied. She was de-cannulated after 24 days, extubated
after 4 days, and discharged to the floor. No change in
ECMO settings occurred during treatment time. The
FiO2 requirement fell from 80% (d − 1) to 40% (d 7), ferritin from 1244 (d − 1) to 535 ng/mL (d 7), and LDH
from 844 (d − 1) to 693 U/L (d 7). MP increased from
11.03 (d − 1) to 20.08 J/minute (d 7), Paw from 15 (d − 1)
to 22 cmH2O (d 7). Minimal changes were noted in
PaCO2, CRP, and D-dimer. She declined rehabilitation
therapy and was discharged home after a total hospital
stay of 38 days.

Discussion
At the doses utilized, no nDA + A treatment-associated toxicities were identified. FiO2 requirements decreased for all
five patients 7 days after nDA + A treatment was initiated,
while measures of lung mechanics varied. All patients were
discharged from the hospital and remain alive at the time of
submission of this report. During the time period that these
patients were treated, ~ 25% mortality was reported during
the first month for patients requiring ICU care within our
hospital system (Richardson et al. 2020). We recognize
that changes in FiO2 levels, lung mechanics, and systemic inflammatory markers may be independent of
the nDA + A treatment. Clinical trials are therefore
required to test the dose range, safety, and efficacy
of dornase alfa in patients with COVID-19 in this
setting and possibly earlier in the disease course.
Endpoints should include measurements of the effect
on respiratory function and mechanics, as well as on
systemic inflammation, coagulopathy, secondary infections, and the presence of NETs in plasma. Eight
such trials were recently registered (NCT04359654,
NCT04355364, NCT04432987, NCT04409925, NCT04
445285, NCT04402944, NCT04402970, NCT0445
9325).
Although it is not yet clear whether nebulized dornase
alfa will have any effect on blood NET levels or systemic
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inflammation in COVID-19, a reduction in systemic inflammatory markers has been reported after use of dornase alfa in patients with cystic fibrosis (Yang and
Montgomery 2018). We did note a reduction in CRP in
two patients (patients 2 and 3) and a reduction in Ddimer in two patients (patients 1 and 2) during nDA + A
treatment. LDH was reduced for the patients on VVECMO during nDA + A treatment, and ferritin was reduced in four out of five patients. Due to the small sample size and the common occurrence of secondary
infections in ventilated patients with COVID-19, we are
unable to comment on any potential relationship between nDA + A administration and the risk of secondary
infections.

Conclusions
This case report suggests that nebulized dornase alfa in combination with albuterol is a safe treatment option, supporting
randomized, controlled clinical trials for mechanically ventilated patients with ARDS secondary to COVID-19, including
for those on VV-ECMO—a patient population with an urgent, unmet need for effective therapies.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s10020-020-00215-w.
Additional file 1 Supplemental Table 1. Additional medications that
dornase alfa+albuterol-treated COVID-19 patients received while in the
hospital.
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